PatientsVille.com Logo

PYREXIA and FOSAMAX

PatientsVille

PYREXIA Symptoms and Causes

A fever is a body temperature that is higher than normal. A normal temperature can vary from person to person, but it is usually around 98.6 F. A fever is not a disease. It is usually a sign that your body is trying to fight an illness or infection.

Infections cause most fevers. You get a fever because your body is trying to kill the virus or bacteria that caused the infection. Most of those bacteria and viruses do well when your body is at your normal temperature. But if you have a fever, it is harder for them to survive. Fever also activates your body's immune system.

Other causes of fevers include

  • Medicines, including some antibiotics, blood pressure medicines, and anti-seizure medicines
  • Heat illness
  • Cancers
  • Autoimmune diseases
  • Some childhood immunizations

Treatment depends on the cause of your fever. If the fever is very high, your health care provider may recommend taking an over-the-counter medicine such as acetaminophen or ibuprofen. Adults can also take aspirin, but children with fevers should not take aspirin. It is also important to drink enough liquids, to prevent dehydration.

Check out the latest treatments for PYREXIA

PYREXIA treatment research studies

FOSAMAX clinical trials, surveys and public health registries


Find Drug Side Effect reports



FOSAMAX Side Effects

Femur Fracture (5674)
Anxiety (3177)
Osteonecrosis (2820)
Fall (2638)
Depression (2384)
Arthralgia (1887)
Dental Caries (1636)
Arthropathy (1621)
Back Pain (1566)
Low Turnover Osteopathy (1355)
Anaemia (1283)
Osteomyelitis (1270)
Hypertension (1242)
Blood Cholesterol Increased (1236)
Impaired Healing (1123)
Abscess (1121)
Adverse Event (1103)
Bone Density Decreased (1051)
Bone Disorder (1050)
Chest Pain (1022)
Bronchitis (915)
Tooth Disorder (890)
Arthritis (849)
Gastrooesophageal Reflux Disease (838)
Intramedullary Rod Insertion (835)
Osteonecrosis Of Jaw (834)
Cataract (805)
Osteoarthritis (784)
Osteoporosis (749)
Pain In Extremity (719)
Stress Fracture (715)
Jaw Disorder (708)
Asthma (706)
Cellulitis (697)
Chronic Obstructive Pulmonary Disease (679)
Abdominal Pain (632)
Diarrhoea (584)
Asthenia (582)
Constipation (557)
Bursitis (552)
Atrial Fibrillation (550)
Pain (544)
Exostosis (531)
Fatigue (522)
Oral Infection (505)
Carpal Tunnel Syndrome (503)
Dizziness (502)
Foot Fracture (501)
Hip Fracture (497)
Headache (477)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

After being on Fosamax for approximately four and one half years suddenly I developed severe medial bilateral knee pain. Have pain when walking down and up stairs. I have NO history of arthritis, no inflammation or redness at the location of pain. I

Can Fosamax cause a drop in blood pressure? Can it worsen pre-existing anaemia. I've taken 4 weekly 70mg tablets and am feeling dizzy and week with loss of sensation in my fingers and joint pains. As I have suffered a year ago from kidney failure

Critical hypertension

Does fosamax affect on teeth cause a major concern. I need it for my bones,but want to keep my teeth!

I feel swollen and feel fatter since starting Fosamax.Weight gain is maybe three lbs but eyes are puffy and face seems swollen. I plan to see my doctor this week. I don't want my osteoporosist to get worse so will most likely stay on it but a diureti

I have been using fosamax for years for osteopenia. I have good teeth with1 root canal. I am wooried about it affecting my teeth. Is taking it a major risk for teeth? Is there a better way to prevent bone loss? I am 64, good health and use weight tra

I have had gastric bypas and would like to know if I can take Fosamax.

I started generic fosamax 10 days ago . After my first dose( sunday)I was fine, but the day after (Monday) in the afternoon I experienced crushing pain in my upper spine that radiated to the front. I had severe difficulty rising f

I took Actonel for 2 months and the psorasis in my scalp got out of control. My Doctor could find no connection. I have been on Fosamax for one month now and the same thing is happening. Have there been other reports of this side effect?

I've heard that it's worse for the bones in the head (teeth, jaw bones, etc.) than anywhere in the body). I'm sure there are exceptions and people who get along fine, but there are WAY too many cases to chance it!

PYREXIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Turnover of Antigen Specific Lymphocytes After Immunization With the Yellow Fever Vaccine
Condition: Yellow Fever
Interventions: Biological: Yellow fever vaccine;   Biological: Yellow fever vaccine and D20 water
Outcome Measures: To evaluate the life span and decay curve of effector CD8 T cells after immunization with 17D yellow fever vaccine;   To evaluate the rate of homeostatic turnover of memory CD8 T cells after immunization with 17D yellow fever vaccine
2 Not yet recruiting Safety and Immunogenicity of Q Fever Vaccine
Condition: Q Fever
Intervention: Biological: Q fever Vaccine
Outcome Measures: Change in Immunogenicity;   Percentage of subjects with symptoms following Q fever vaccination;   Percentage of subjects with erythema following Q fever vaccination along with severity and association with vaccination;   Percentage of subjects with induration following Q fever vaccination along with severity and association with vaccination;   Percentage of subjects with each AE, system organ class of AE, severity, and association with vaccination;   Percentage of subjects with symptoms following Q fever skin test antigen;   Percentage of subjects with erythema following Q fever skin test antigen along with severity and association with skin test antigen;   Percentage of subjects with induration following Q fever skin test antigen along with severity and association with skin test antigen;   Percentage of subjects with each AE, system organ class of AE, severity, and association with skin test antigen
3 Recruiting Respiratory Physiology in Children With Febrile Seizures.
Conditions: Febrile Illness in Children;   Seizures, Febrile
Intervention:
Outcome Measures: Change of transcutaneous pCO2 per change of body temperature [mmHg/degree C];   Change of respiratory rate per change of body temperature [1/sec * degree C];   Change of transcutaneous pCO2 per change of respiratory rate [mmHg * sec]
4 Recruiting Etiologies of Fever Among Adults in Dar es Salaam
Condition: Acute Febrile Illnesses
Intervention:
Outcome Measures: Proportion of patients with each disease among all febrile patients, overall and stratified by HIV status;   Proportion of febrile patients with acute respiratory infection infected with a certain respiratory pathogen, compared to the proportion of healthy controls infected with the same pathogen.
5 Recruiting Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma
Condition: Soft Tissue Sarcoma
Intervention: Radiation: Hyperthermia and Proton Beam
Outcome Measures: To evaluate safety of hyperthermia and proton beam treatment in unresectable soft tissue sarcomas;   To evaluate the local response to hyperthermia and proton beam therapy as a preoperative regimen for unresectable soft tissue sarcomaLocal control
6 Not yet recruiting Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO
Conditions: Febrile Neutropenia;   Hematological Malignancy
Intervention: Drug: Discontinuation of imipenem-cilastatin or meropenem
Outcome Measures: The percentage of patients with failed treatment;   All-cause mortality;   Infection-related mortality;   The length of hospitalization in days;   Unexpected re-admission other than for planned chemotherapy or other elective treatment.;   The recurrence of fever within 24 hours after discontinuation of antibiotic therapy.;   The total number of febrile episodes during neutropenia;   Time to defervescence;   Antibiotic or antifungal treatment within 30days after discharge other than standard antibiotic prophylaxis.;   Incidence and prevalence of Clostridium difficile infection;   Incidence and prevalence of liver and kidney dysfunction;   Candida spp. colonization in (surveillance) cultures;   Cost of antimicrobial therapy per admission;   MASCC-score;   The percentage of patients with mucositis and positive blood cultures or short treatment failure.;   Bacterial resistance in blood cultures and surveillance cultures (including minimal inhibitory concentrations (MIC)).
7 Recruiting Human Immune Responses to The Yellow Fever Virus Vaccine
Condition: Yellow Fever
Intervention: Biological: Yellow fever vaccine
Outcome Measures: 1. Isolation and characterization of yellow fever vaccine (YFV-17D) specific adaptive immune responses: characterize the magnitude and quality of YFV specific T cell responses, antibody secreting cells and memory B cells.;   Determine the signatures of innate immune responses: cytokines, chemokines, dendritic cells and microarray analyses on peripheral blood mononuclear cells
8 Unknown  A Screening Strategy for Q Fever Among Pregnant Women
Condition: Q Fever
Intervention: Other: screening
Outcome Measures: obstetric or maternal complications in Q fever positive women;   course of infection in pregnant women;   the accuracy of the diagnostic tests used for screening;   placentitis;   costs
9 Recruiting Pilot Study of a Catheter-based Ultrasound Hyperthermia System
Conditions: Cervical Cancer;   Prostate Cancer
Interventions: Procedure: Hyperthermia;   Radiation: HDR brachytherapy
Outcome Measures: Evaluate the safety and tolerability of interstitial and endocavitary ultrasound hyperthermia therapy;   Evaluate the feasibility, defined as being able to administer hyperthermia at a specified temperature range and thermal dose.;   Characterize the interstitial and endocavitary ultrasound heating technology by describing the thermal parameters including attainable temperature and thermal dose distribution and duration at the tumor treatment region.
10 Unknown  West Indies-French Guiana Dengue Study
Conditions: Fever;   Dengue
Interventions: Other: biological sample collection;   Other: quality of life questionnaire EuroQol®
Outcome Measures: Occurrence, during follow-up (for 12 weeks following symptom onset), of shock, internal bleeding, failure of one or several organs or systems (brain, heart, lung, liver, kidney, clotting system), or death.;   Onset of dengue hemorrhagic fever (WHO criteria). Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.
11 Recruiting Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
Conditions: Visceral Leishmaniasis;   Human African Trypanosomiasis;   Enteric Fever;   Melioidosis;   Brucellosis;   Leptospirosis;   Relapsing Fever;   Rickettsial Diseases;   HIV;   Tuberculosis;   Malaria;   Amoebic Liver Abscess
Interventions: Device: rk28 ICT;   Device: IT LEISH (rK39);   Device: Immunochromatographic HAT test;   Device: HAT Serostrip;   Device: Card Agglutination Trypanosoma Test (CATT)-10;   Device: Typhidot M;   Device: S. typhi IgM/IgG;   Device: Test-it Typhoid IgM;   Device: Test-it Leptospirosis IgM;   Device: Leptospira IgG/IgM
Outcome Measures: Prevalence of Visceral Leishmaniasis (VL), Human African Trypanosomiasis (HAT) and other Neglected Tropical Diseases (NTDs);   Identification of clinical and laboratory diagnostic indicators;   Identification of reliable Rapid Diagnostic Tests (RDTs);   Predictive values of RDTs;   Cost-effectiveness of the diagnostic tests
12 Recruiting Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
Conditions: Enteric Fever;   Typhoid Fever
Interventions: Drug: Ceftriaxone;   Drug: Gatifloxacin
Outcome Measures: Rate of treatment failure;   Time to fever clearance;   S.typhi or S.paratyphi carriage;   Number of adverse events;   Household transmission
13 Recruiting Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage
Condition: Fever
Interventions: Drug: Intravenous Ibuprofen;   Drug: Acetaminophen (Standard of Care)
Outcome Measures: Fever Burden;   Inflammatory Markers;   Cost analysis;   Bleeding Incidence
14 Recruiting Reliability of Subjective Assessment of Fever by Parents and Health Care Providers in Children and Adolescents
Condition: FEVER
Intervention:
Outcome Measure: subjective assessment of fever by both parents and medical personnel will be unreliable
15 Recruiting A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Device: ThermalCore Hyperthermia System
Outcome Measures: Organ toxicity;   Time To Progression of Disease
16 Recruiting Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
Condition: Breast Cancer
Intervention: Drug: ThermoDox in combination with Microwave Hyperthermia (heat)
Outcome Measures: To determine the bioequivalence of ThermoDox when used with hyperthermia among patients with RCW breast cancer.;   To determine efficacy of ThermoDox in combination with Hyperthermia;   To evaluate the safety of ThermoDox in combination with Hyperthermia
17 Recruiting Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer
Condition: Rectal Cancer
Interventions: Radiation: Radiotherapy;   Procedure: Hyperthermia;   Drug: 5-Fluorouracil;   Drug: Capecitabine;   Drug: Oxaliplatin
Outcome Measures: Feasibility rate (i.e. rate of patients not experiencing dose-limiting toxicity [DLT]);   Number of hyperthermia applications by patient;   Local progression-free survival;   Distant metastasis-free survival;   Overall survival;   Response rate;   Rate of R0-resections;   Rate of acute and late toxicity
18 Unknown  Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Biological: recombinant interferon alfa;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Procedure: hyperthermia treatment
Outcome Measures: Tumor response;   Toxicity;   Survival;   Changes in quality of life;   Conversion of inoperable tumors to operable;   Changes in cellular and cytokine immune function
19 Recruiting Effectiveness of the Combined Whole Liver Irradiation (WLI) and Hyperthermia for Gastrointestinal Tract Cancer Liver Metastasis
Condition: The Patients With Unresectable Chemoresistant Multiple Liver Metastasis From Colorectal Cancer
Intervention: Radiation: Combined hyperthermia and radiation therapy
Outcome Measures: Time to local tumor progression after combined hyperthermia and RT;   Objective response rate of combined hyperthermia and RT;   Change from baseline quality of life at 3 months;   Local tumor progression free survival rate after combined hyperthermia and RT;   Adverse event after combined hyperthermia and RT.;   Overall survival rate after combined hyperthermia and RT
20 Unknown  Oral Versus Rectal Ibuprofen for Fever in Young Children - a Randomized Control Study.
Condition: Fever
Interventions: Drug: Ibuprofen suppository;   Drug: Ibuprofen Suspension
Outcome Measures: Maximal change in temperature during the 4-hour period after enrollment.;   Proportion of patients with a drop of at least 1°C and 2°C in mean temperature at 4h. Decrement in fever at each time point, and the area under the temperature (versus time) curve. Proportion of patients with temperature < 38 at 4 hours.